Multiple Sclerosis Clinical Trial
Official title:
Assessment of Patient Use of a New Device: RebiSmart
Multiple sclerosis (MS) is a chronic disease which causes inflammation and destruction of
the nerves in within the brain and the spinal cord. This disease is one of the most common
causes of disability in young adults. A ''relapse'' is a phenomenon that occurs when there
is an acute attack of disability as a result of an acute attack on the nervous system. There
is usually some degree of recovery after a relapse.
Rebif is licensed in the United Kingdom for the treatment of relapsing MS and is given 3
times a week by injections under the skin. The RebiSmart device is a new injection device
which has been developed to help patients with injecting their Rebif treatment.
Currently, all treatments for MS are injectable and require long term patient commitment.
Patient compliance to treatment is important for the therapy to work effectively and
decrease the risk of relapse episodes. Using a device that makes it easy for patients to
inject may potentially improve compliance to treatment and therefore potentially have an
impact on the number of relapses patients experience. The RebiSmart device has been
developed for patients to inject conveniently and in comfort. The device allows the patient
to control certain parameters such as needle depth, needle speed, injection time etc, and
also has extra features designed to ease the injection process, such as a dose history
calendar and an onâscreen injection guide. The aim of this study is to determine what
percentage of patients liked using the RebiSmart device and found it ''easy'' or ''very
easy'' to use. The study will also determine which of the device features were most useful
to the patients.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
| Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
| Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
| Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
| Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
| Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
| Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
| Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
| Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
| Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
| Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
| Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
| Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
| Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |